left-arrow right-arrow pinterest facebook google_plus linkedin

Alliance A021502

Status:

Recruiting | Phase III 

Official Title:

Testing the Addition of the Antibody Atezolizumab to Usual Chemotherapy after Surgery in Patients with Colon Cancer

Study Purpose:

The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone.

Interventions:

  • Group 1: Chemotherapy plus atezolizumab for 6 months, then atezolizumab alone for 6 months

  • Group 2: Chemotherapy for 6 months

  • Quality of Life surveys

  • After completion of the study patients will be followed for 8 years

Key Participation Requirements: 

Gender: 

Male or Female

Age:

19 years and older

Diagnosis:

Stage III Colon cancer

Eligibility: 

Stage III colon cancer that has been removed by surgery.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

Alliance A021502

For more information, visit the U.S. National Library of Medicine clinical trial database

To learn more about this clinical trial please contact us today!